Key result
The DVVconfirm assay was highly sensitive to the anticoagulant effect of rivaroxaban and demonstrated a strong correlation with prothrombin time in patients on vitamin K antagonists.
Why the study?
Does the DVVconfirm assay accurately measure the anticoagulant effect of rivaroxaban in treated patients?
Observational (n=220)
Does the DVVconfirm assay accurately measure the anticoagulant effect of rivaroxaban in treated patients?
The DVVconfirm assay using Russell's viper venom provides a rapid and sensitive method for measuring the anticoagulant effect of rivaroxaban in whole plasma.
Answers are grounded in this paper and cite their sources.
Supports DVVconfirm for rivaroxaban effect assessment; leaves open prospective validation before clinical adoption.
BACKGROUND: New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in some special circumstances. METHODS: Following administration of rivaroxaban to patients, at the likely peak and trough activity times, we assessed the effects on prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and clotting time using Russell's viper venom, and in the presence of phospholipids and calcium reagent available as DVVreagent® and DVVconfirm®. The data were used to determine an adequate NOAC plasma level based on anticoagulant activities expressed as a ratio (patients/normal, R-C). RESULTS: DVVconfirm as R-C could be rapidly performed, and the results were reasonably sensitive for rivaroxaban and probably for other FX inhibitors. This assay is not influenced by lupus anticoagulant and heparin, does not require purified NOAC as control, and will measure whole-plasma clotting activity. CONCLUSIONS: We propose a cut-off R-C value of 4.52 ± 0.33 for safety, but clinical studies are needed to establish whether this cut-off is useful for identifying patients at increased risk of hemorrhage or exhibiting low anticoagulation effect. It also seems possible that normal R-C could indicate an absence of anticoagulant activity when rivaroxaban is discontinued due to episodes of uncontrolled bleeding during anticoagulation or for emergency surgery.
No takes yet. Share an insight, caveat, or question.
Altman et al. (2014) conducted an observational in Patients requiring anticoagulation (Atrial Fibrillation, Deep Vein Thrombosis) (n=220). DVVconfirm assay vs. Standard coagulation assays (PT, aPTT, TT) was evaluated on Correlation between R-PT and R-C (DVVconfirm ratio) in patients treated with warfarin (r = 0.78, 95% CI 0.71-0.84, p=<0.001). The DVVconfirm assay was highly sensitive to the anticoagulant effect of rivaroxaban and demonstrated a strong correlation with prothrombin time in patients on vitamin K antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: